相似文献
1
What else can the immune system recognize?免疫系统还能识别什么？
Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11509-10. doi: 10.1073/pnas.95.20.11509.
2
Monoclonal antibody recognition of cholesterol monohydrate crystal faces.
Chem Biol. 1996 Jul;3(7):567-77. doi: 10.1016/s1074-5521(96)90148-9.
3
Structural and chemical complementarity between antibodies and the crystal surfaces they recognize.
Proteins. 1999 Feb 15;34(3):383-94.
4
Monoclonal antibodies that specifically recognize crystals of dinitrobenzene.
FASEB J. 1996 Oct;10(12):1435-42. doi: 10.1096/fasebj.10.12.8903514.
5
RT-PCR cloning and characterization of mouse immunoglobulin variable domains with high affinity for HLA-DR antigens.对HLA - DR抗原具有高亲和力的小鼠免疫球蛋白可变区的RT - PCR克隆与特性分析
Immunogenetics. 1997;46(3):249-50. doi: 10.1007/s002510050270.
6
Prospects for human monoclonal antibodies: a critical perspective.人源单克隆抗体的前景：批判性视角
Yale J Biol Med. 1982 May-Aug;55(3-4):297-303.
7
Conformational changes in a Vernier zone region: Implications for antibody dual specificity.游标区构象变化：对抗体双特异性的影响。
Proteins. 2020 Nov;88(11):1447-1457. doi: 10.1002/prot.25964. Epub 2020 Jul 3.
8
At the crossroads of chemistry and immunology: catalytic antibodies.化学与免疫学的交叉领域：催化抗体。
Science. 1991 May 3;252(5006):659-67. doi: 10.1126/science.2024118.
9
The polyclonal expression of immunoglobulin variable region determinants on the membrane of B cells and their precursors.免疫球蛋白可变区决定簇在B细胞及其前体细胞表面的多克隆表达。
Springer Semin Immunopathol. 1980 Aug;3(2):171-211. doi: 10.1007/BF02053975.
10
Amino acid sequence of a phosphocholine-binding antibody from an immune defective CBA/N mouse employing the T15 VH region associated with unusual DH, JH, and V kappa segments.利用与异常重链多样性基因（DH）、重链连接基因（JH）和κ轻链可变区（Vκ）片段相关的T15重链可变区（VH），从免疫缺陷的CBA/N小鼠中获得的一种磷酸胆碱结合抗体的氨基酸序列。
J Immunol. 1984 Mar;132(3):1544-9.
引用本文的文献
1
Safety risk management for low molecular weight process-related impurities in monoclonal antibody therapeutics: Categorization, risk assessment, testing strategy, and process development with leveraging clearance potential.单克隆抗体治疗药物中小分子工艺相关杂质的安全性风险管理：利用清除潜能进行分类、风险评估、测试策略和工艺开发。
Biotechnol Prog. 2021 May;37(3):e3119. doi: 10.1002/btpr.3119. Epub 2021 Jan 6.
2
Biocompatibility of Biomaterials for Nanoencapsulation: Current Approaches.用于纳米封装的生物材料的生物相容性：当前方法
Nanomaterials (Basel). 2020 Aug 22;10(9):1649. doi: 10.3390/nano10091649.
3
Hide and Seek: Nanomaterial Interactions With the Immune System.捉迷藏：纳米材料与免疫系统的相互作用。
Front Immunol. 2019 Feb 1;10:133. doi: 10.3389/fimmu.2019.00133. eCollection 2019.
4
Development and characterization of antibody reagents for detecting nanoparticles.用于检测纳米颗粒的抗体试剂的开发与特性分析
Nanoscale. 2015 Dec 21;7(47):20042-54. doi: 10.1039/c5nr04882f. Epub 2015 Nov 16.
5
Understanding the correlation between in vitro and in vivo immunotoxicity tests for nanomedicines.理解纳米药物的体外和体内免疫毒性测试之间的相关性。
J Control Release. 2013 Dec 10;172(2):456-66. doi: 10.1016/j.jconrel.2013.05.025. Epub 2013 Jun 3.
6
Proteomic analysis of early response lymph node proteins in mice treated with titanium dioxide nanoparticles.用二氧化钛纳米粒子处理的小鼠早期淋巴结蛋白的蛋白质组学分析。
J Proteomics. 2011 Nov 18;74(12):2745-59. doi: 10.1016/j.jprot.2011.08.009. Epub 2011 Aug 22.
7
Do nanomedicines require novel safety assessments to ensure their safety for long-term human use?纳米药物是否需要全新的安全性评估以确保其对人类长期使用的安全性？
Drug Saf. 2009;32(8):625-36. doi: 10.2165/00002018-200932080-00002.
本文引用的文献
1
THE MANUFACTURE OF ANTIBODIES IN VITRO.体外抗体的制造。
J Exp Med. 1942 Aug 1;76(2):211-20. doi: 10.1084/jem.76.2.211.
2
Structural and chemical complementarity between antibodies and the crystal surfaces they recognize.
Proteins. 1999 Feb 15;34(3):383-94.
3
Antigenicity of fullerenes: antibodies specific for fullerenes and their characteristics.富勒烯的抗原性：针对富勒烯的特异性抗体及其特性
Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10809-13. doi: 10.1073/pnas.95.18.10809.
4
Monoclonal antibodies that specifically recognize crystals of dinitrobenzene.
FASEB J. 1996 Oct;10(12):1435-42. doi: 10.1096/fasebj.10.12.8903514.
5
Biological applications of fullerenes.富勒烯的生物学应用。
Bioorg Med Chem. 1996 Jun;4(6):767-79. doi: 10.1016/0968-0896(96)00081-8.
6
Monoclonal antibody recognition of cholesterol monohydrate crystal faces.
Chem Biol. 1996 Jul;3(7):567-77. doi: 10.1016/s1074-5521(96)90148-9.
7
Interactions of protein antigens with antibodies.蛋白质抗原与抗体的相互作用。
Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):7-12. doi: 10.1073/pnas.93.1.7.
8
T cell-independent antigens type 2.2型非T细胞依赖性抗原
Annu Rev Immunol. 1995;13:655-92. doi: 10.1146/annurev.iy.13.040195.003255.
9
Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 A resolution.流感病毒糖蛋白抗原神经氨酸酶在2.9埃分辨率下的结构。
Nature. 1983;303(5912):35-40. doi: 10.1038/303035a0.
10
A heterologous immunoglobulin chain recombinant carries a distinct site for dinitrophenyl and obeys the common hapten binding mechanism.一种异源免疫球蛋白链重组体带有一个独特的二硝基苯基位点，并遵循常见的半抗原结合机制。
Biochemistry. 1981 Aug 18;20(17):5011-8. doi: 10.1021/bi00520a030.
Zotero 插件